Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

21.94 +0.32 (+1.48%)
Official Closing Price Updated: 4:15 PM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
2 Magnificient Growth Stocks I'm Buying in August ↗
These biotech stocks could markedly outperform the broader market. 
Via The Motley Fool
News headline image
Vivek 'Da Vek' Ramaswamy: The 2024 Presidential Candidate Who Might Just Rap His Inauguration Speech ↗
Donald Trump and Ron DeSantis have been the runaway favorites for the GOP nomination in the 2024 election, but there’s one candidate that has been climbing up the polls and gaining support from... 
Via Benzinga
News headline image
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
From Roivant Sciences
Via GlobeNewswire
News headline image
3 Biotech Stocks for Getting Rich in 2023 ↗
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist. 
Via InvestorPlace
News headline image
2 Nasdaq Stocks That Could Soar This Week ↗
BridgeBio Pharma and Roivant Sciences could make big moves this week. 
Via The Motley Fool
News headline image
Roivant Sciences's Return on Invested Capital Insights ↗
 
Via Benzinga
News headline image
Analyst Expectations for Roivant Sciences's Future ↗
 
Via Benzinga
News headline image
Why Shares of Roivant Sciences Rose Wednesday ↗
The pharmaceutical company released fourth-quarter earnings. 
Via The Motley Fool
News headline image
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover ↗
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed. 
Via Investor's Business Daily
News headline image
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
Via Benzinga
News headline image
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others 
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Roivant Sciences Stock is Trading Higher Today ↗
Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with  
Via Benzinga
News headline image
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market... 
Via Benzinga
News headline image
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness' ↗
 
Via Benzinga
News headline image
A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout ↗
The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis. 
Via Investor's Business Daily
News headline image
5 Analysts Have This to Say About Roivant Sciences ↗
 
Via Benzinga
News headline image
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Roivant Sciences Stock Is Perking Up Today ↗
Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock. 
Via The Motley Fool
News headline image
Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
News headline image
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
From Roivant Sciences
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 ↗
 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission ↗
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old... 
Via Benzinga
News headline image
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug? ↗
Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.